Biological understanding of top genetic alterations in leukemia
Novel anti-cancer drug targeting
Reactivation of mutant p53
Studies related to p53 molecular mechanisms
Testing small molecules or biologics for cancer drug development
Biosafety Level
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Comments
The Leukemia p53 Hotspot Mutation Cell Panel is composed of six select suspension cell lines derived from individuals with leukemia. The mutations have been sequenced and validated by ATCC. This panel includes p53 wild type cell lines as well as p53 mutant lines that carry hotspot mutations in one of the following codons: 175, 248 and 273.
